Posted by Michael Wonder on 15 Oct 2025
Corcept submits marketing authorisation application to EMA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer
14 October 2025 - Corcept Therapeutics has submitted a marketing authorisation application to the EMA for relacorilant to treat patients with platinum-resistant ovarian cancer.
Corcept’s marketing authorisation application submission is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials.
